July 30, 2016 11:52 PM ET


Company Overview of Oncopeptides AB

Company Overview

Oncopeptides AB is a clinical stage pharmaceutical development company that develops cytosuperior chemotherapeutic pharmaceuticals of existing basic cytotoxic compounds for cancer treatment. Its product includes Melflufen, a cytosuperior of the chemotherapeutic alkylator melphalan that is accumulated in cancer cells for targeting multiple myeloma. The company is headquartered in Stockholm, Sweden.

Västra Trädgårdsgatan 15

Stockholm,  111 53



46 7 05 69 54 71

Key Executives for Oncopeptides AB

Chief Executive Officer
Age: 44
Compensation as of Fiscal Year 2016.

Oncopeptides AB Key Developments

Oncopeptides AB Presents at BioEquity Europe 2016 Conference, May-10-2016

Oncopeptides AB Presents at BioEquity Europe 2016 Conference, May-10-2016 . Venue: Scandic Hotel, Vester Soegade 6, 1601 Copenhagen, Denmark.

Oncopeptides AB Presents at BIO-Europe Spring 2016, Apr-06-2016 09:15 AM

Oncopeptides AB Presents at BIO-Europe Spring 2016, Apr-06-2016 09:15 AM. Venue: Kistamässan Convention Center, Stockholm, Sweden.

Oncopeptides AB Presents Efficacy Results of Melflufen in Combination with Dexamethasone from an Ongoing Open-Label Phase 2 Study

Oncopeptides AB presented clinical results from an ongoing Phase 2 study in patients with relapsed and relapsed refractory multiple myeloma. The results, presented at the American Society of Hematology, in Orlando, Florida showed an overall response rate (partial response or better) of 41% and clinical benefit rate (minimal response or better) of 56% in efficacy evaluable patients. At the date of analysis, the median progression-free survival was 9.4 months. Melflufen showed promising activity in heavily pre-treated RRMM patients where conventional therapies have failed and rates were similar across the different patient refractory status groups (single, double and triple refractory patients). The results are from a clinical trial being carried out across four centers in Europe (Sweden, Italy, the Netherlands and Denmark) and two in the USA (Boston, MA and Chapel Hill, NC) and cover; Safety and tolerability, treatment and disposition, efficacy and baseline characteristics. The results support Oncopeptides’ belief that melflufen has the potential to provide an alternative when conventional therapies have failed in RRMM patients. Melflufen is a peptidase-potentiated therapy and a potent antiangiogenic compound. It triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA.

Similar Private Companies By Industry

Company Name Region
Abunon AB Europe
AcuCort AB Europe
Aditech Pharma AB Europe
Antarctic Pharma Europe
Apotek Produktion & Laboratorier AB Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Oncopeptides AB, please visit www.oncopeptides.se. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.